Kinnate Biopharma Inc. has synthesized mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors reported to be useful for the treatment of cancer.
Kinnate Biopharma Inc. and affiliated organizations recently reported preclinical data for the novel brain-penetrant combination therapy using the MEK inhibitor KIN-7136 and the RAF inhibitor KIN-8391, as a novel therapeutic strategy for the treatment of melanoma brain metastasis.
Research at Kinnate Biopharma Inc. has led to the development of mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors reported to be useful for the treatment of cancer.
Having cast around for other routes, Histogen Inc. is throwing in the towel, its board having adopted a shutdown plan that includes the distribution of remaining cash to stockholders after a wind-down of operations. One of the company’s West Coast peers, Kinnate Biopharma Inc., had news, too. The firm disclosed the layoff of 70% of its workforce, including all employees at the Shanghai-based subsidiary Kinnjiu Biopharma Inc., leaving the outfit with 28 full timers.
Kinnate Biopharma Inc. has added two new internally developed next-generation development candidates to its targeted oncology pipeline, a brain-penetrant mitogen-activated protein kinase kinase (MEK) inhibitor and a highly selective hepatocyte growth factor receptor gene (c-Met) inhibitor.
Amid the trend of investors partnering with Western biotech companies to set up China-focused joint ventures, San Diego-based Kinnate Biopharma Inc. has joined Orbimed Asia Partners, Orbimed Private Investments and Foresite Capital to establish a JV in Shanghai to move its preclinical kinase inhibitor candidates forward in greater China.
Kinnate Biopharma Inc., a San Diego-based company focused on the discovery and development of small-molecule kinase inhibitors for genomically defined cancers, has raised $98 million in a series C financing.
